In patients with advanced RCC, second-line treatment with LEN + EVE prolonged progression-free survival (PFS) compared with EVE alone. LEN + PEMBRO, also showed preliminary efficacious evidence in a phase 1/2 RCC study. Here, we describe the investigational study results of first-line LEN + PEMBRO or LEN + EVE versus SUN in pts with advanced RCC.
Key topics that will be discussed during the call include, among other things…any notable results from the CLEAR dataset, the biggest advantages and drawbacks, and how the combo compares to other regimens on efficacy, safety and overall risk/benefit, response rate, progression-free survival, and much more in first-line RCC.
Detailed CLEAR results will be presented on February 13 and should go a long way towards clarifying how and when Keytruda/Lenvima stacks up against the likes of other regimens involving an anti-PD-(L)1 mAb plus tyrosine kinase inhibitor or two immuno-oncology (I/O) drugs:
Phase 3 trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) or everolimus (EVE) versus sunitinib (SUN) monotherapy as a first-line treatment for patients (pts) with advanced renal cell carcinoma (RCC) (CLEAR study).
